Swiss National Bank Increases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Swiss National Bank increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,900 shares of the company’s stock after acquiring an additional 1,000 shares during the period. Swiss National Bank owned approximately 0.15% of Protagonist Therapeutics worth $3,354,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth approximately $399,000. Thrivent Financial for Lutherans purchased a new position in Protagonist Therapeutics during the third quarter worth $2,082,000. Intech Investment Management LLC bought a new position in Protagonist Therapeutics during the third quarter valued at $861,000. Charles Schwab Investment Management Inc. increased its position in Protagonist Therapeutics by 7.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after acquiring an additional 39,850 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Protagonist Therapeutics by 26.7% in the third quarter. Cerity Partners LLC now owns 14,241 shares of the company’s stock valued at $641,000 after acquiring an additional 3,005 shares during the period. 98.63% of the stock is owned by institutional investors.

Insider Activity

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the transaction, the director now directly owns 13,130 shares of the company’s stock, valued at approximately $712,302.50. The trade was a 23.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 64,776 shares of company stock worth $3,585,010. 5.40% of the stock is currently owned by company insiders.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $49.56 on Thursday. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of 18.63 and a beta of 2.34. The firm’s 50-day moving average is $42.04 and its two-hundred day moving average is $42.82. Protagonist Therapeutics, Inc. has a 1 year low of $24.22 and a 1 year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $54.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 10th. JMP Securities reiterated a “market outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. Wedbush restated an “outperform” rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, March 11th. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, BMO Capital Markets upped their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.56.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.